Eppendorf ’s Post

We are a sponsor of the 8th Liquid Biopsy Precision Summit in San Diego, February 28 - March 1! Join us for Dr. Albitar's talk at 10:00am, Thursday Feb 29th on “Using Cell-Free RNA to Increase the Clinical Versatility of Liquid Biopsy”. Some insights we’ll share: - Using cfRNA in predicting diagnosis and prognosis - Using cfRNA to enhance detection of minimal residual disease (MRD) - Using cfRNA to predict flow cytometry and immunohistochemistry findings Come learn how RNA is a game changer. #Sysmexinostics #8thLiquidBiopsyPrecisionSummit https://hubs.la/Q02h4tJ70

Decoding disease insights from multimodal data: Our newest preprint demonstrates how researchers can apply Ozette Discovery™ to leverage the multimodal protein and RNA signal from #CITEseq data to identify predictors of disease severity. CITE-seq simultaneously measures protein and RNA expression at the single cell level—but the protein expression data is often underutilized. Harnessing Ozette Discovery™–a computationally-driven method used for flow cytometry data analysis– we reanalyze a previously published COVID-19 CITE-seq dataset. The results:  ➡️ Instantaneous identification of granular, robust, and interpretable cell phenotypes ➡️ Over 100 robust phenotypes identified compared to the original publication, including novel subpopulations associated with COVID-19 disease severity ➡️ Precise interrogation of transcriptional programs underpinning disease-associated cellular phenotypes Download the preprint to learn how Ozette Discovery™ delivers computationally-derived insights at unmatched speed and resolution. Link in comments. Congratulations to Ozette team members: Denise Allen, PhD, Matthew Weaver, Sam Prokopchuk, Fritz Lekschas, Mike Jiang, Greg Finak, Evan Greene, and Andrew McDavid. #singlecell #celldiscovery

Live from SITC: Unlock the most value of your tissue with MIBIplus! 🌟 Hey there, SITC attendees! We're thrilled to be here at the conference, and we've got something truly exciting to share with you. Make your way to Booth #1107 and let’s talk MIBIplus, our new spatial proteomics all-in-one service! Unleash the Power of MIBIplus  With the MIBIscope technology at its core, MIBIplus empowers you to detect over 40 immuno-oncology relevant cell types in both the tumor and its microenvironment within one tissue section. Dive deep into your samples and uncover answers like never before. With MIBIplus, you will: Be in control of your data interpretation 📊 Seamlessly go from tissue to answers 👨🔬👩🔬 Maximize the value of your tissue samples 🧪 We will also have live demos of our analysis tools, including MIBIsight! Come see how your data analysis can be simplified today at 12:30 PM and 6 PM or tomorrow at 12:30 PM and 7:30 PM. So, what are you waiting for? Come see it all in action at Booth #1107. Let's chat, explore, and envision the future of cancer research together. Your questions and curiosities are welcome! 🚀 #SITC2023 #MIBIplusAtSITC #CancerResearch #SpatialProteomics Not here? Don't fear, you can also learn more at: https://lnkd.in/g5p_7Pgd

Join our next roundtable to learn about the importance of proteomics data & how researchers are combining it with other multimodal data to power research breakthroughs. Register today: https://hubs.ly/Q02y8fQp0

Profiling our immune system involves identifying and differentiating unique white blood cells (WBCs) that defend our bodies against various harmful external or internal factors, such as infections, cancer, and heart disease. This is done by measuring specific proteins present on these WBCs, which allows us to distinguish one cell type from another. The greater the variety of proteins we can measure, the more precisely we can identify and characterize each unique cell. This detailed profiling enhances our understanding of how our immune system operates and its role in protecting our health. Below is our new pre-print that demonstrates significant advances in our single cell analysis infrastructure where we apply #Ozette Discovery to multimodal single cell protein and RNA data from #CITEseq to identify cellular phenotypes associated with critical #COVID severity. We are able to robustly characterize the cellular phenotypes using protein measurements and then interrogate those homogeneous cell populations for transcriptional changes, which providing insights into the mechanisms of COVID severity. This is a sneak peek to the future of how we think about multimodal data analysis at Ozette to unlock the power of the immune system and accelerate therapeutic development. Congratulations to the Ozette team on this milestone! #immuneprofiling #immunotherapy #singlecell

Extracellular vesicles (EVs) show great promise as useful biomarkers for disease detection and monitoring. We have recently reported a label-free technique for mapping and distinguishing EVs from different cell types and cell states requiring only very small sample volumes. Sarah Bamford and the La Trobe team used ToF-SIMS and our SOM-RPM machine learning workflow to explore the resulting hyperspectral data sets for discrete EVs and small aggregates at the sub micrometer scale. The study has been reported in the Journal of Excellular Biology, in collaboration with Natasha Vassileff, Jereme G. Spiers and Andy Hill. Read about our work: https://lnkd.in/gehZDkXb #SOM-RPM #extracellularvesicles #tofsims #machinelearning

It was great to participate in the BioCentury Inc. East-West Biopharma Summit panel with Simone Fishburn and Andy Plump. We discussed a range of topics with a focus on our collective efforts to drive innovation and help patients suffering from serious diseases. Highlighted topics included sequential immunotherapy for autoimmunity; scientific advances to define causal human biology; novel therapeutic modalities to match to molecular mechanism; and key challenges to improve R&D productivity.    #BioCenturyEastWest #lifesciences #DrugDiscovery #BMS_Employee   https://lnkd.in/ecXnxxbB  

Discover the 🔑 to long-term success with humanized immune system (HIS) models. Dr. Elinor Willis joined Taconic to share her breakthrough findings on myeloid cell hyperactivation in key models and the impact to study design and timelines. Watch the presentation here: https://bit.ly/3W4PdYw

📣 For ESMO members: Breaking Science in #GastrointestinalCancers. Michel P. Ducreux presents his findings on Sequences of regorafenib and trifluridine/tipiracil after failure of standard therapies for mCRC. 👉 Explore this video and the entire series on OncologyPRO now. 🔗 https://ow.ly/guAY50SFi6l